In the Sweet Spot · · Boston Scientific (BSX) · Healthcare

Why Boston Scientific Stands Out Today

A cyberattack-driven guidance cut has pushed Boston Scientific near its 52-week low, and the resulting price drop has lifted its projected return squarely into our sweet spot even as its quality percentile stays near the very top of our coverage.

Boston Scientific (BSX) was Manifest Investing's In the Sweet Spot daily stock pick for September 11, 2026. At the time of the pick, Boston Scientific carried a quality percentile of 99 and a projected annual return (PAR) of 19.2% against a MIPAR of 9.6%, placing it inside the sweet spot of 14.6% to 19.6%.

Key metrics at the time of the pick

Quality percentile
99
Projected annual return (PAR)
19.2%
MIPAR (median PAR of coverage)
9.6%
PROVE
13.8%
Core score (of 300)
287
Financial strength (of 100)
97
EPS stability (of 100)
91.5
Sales growth forecast
10.8%
P/E ratio
17.9
Price at pick
$43.10
52-week low
$42.20
52-week high
$105.72
Above 52-week low
2.1%
Below 52-week high
59.2%
Dividend yield
0.0%
Projected yield
0.0%
In the sweet spot
Yes
Triple play
No

Boston Scientific (BSX) is one of the highest-quality names we follow, and this week’s news has pushed its price low enough that our projected return has moved into the range we watch most closely.

What happened today. The company disclosed that products are now moving through its distribution network at or above normal levels following an August cyberattack, but it also told investors it is unlikely to meet its 2026 guidance because of the disruption, according to reporting from Barron’s and the Wall Street Journal. The stock fell sharply on the news, per Zacks, and closed most recently at $43.10, just 2.1% above its 52-week low of $42.20 and 59.2% below its 52-week high of $105.72.

How our methodology reads it. PAR (Projected Annual Return, our five-year forecast of annualized return combining expected price appreciation and dividend yield) is 19.2% for Boston Scientific. With MIPAR, the median PAR across everything we follow, at 9.6%, the sweet spot we define runs from 14.6% to 19.6% (five to ten percentage points above MIPAR). BSX’s 19.2% sits inside that band. PAR moves inversely to price, so part of the reason the projected return looks this attractive is precisely because the price has fallen; that is the arithmetic working as intended, not a signal to chase the stock.

Quality, meanwhile, is essentially as high as it gets: a percentile rank of 99.3, in the top 1% of everything we track. That’s built from a financial strength score of 96.7 out of 100 and an EPS predictability score of 91.5 out of 100 (both very high on their 0-100 scales), alongside relative sales growth and profitability measures. Sum quality, financial strength, and EPS stability together and you get a core score of 287 out of a possible 300, well above the 225 threshold we associate with core-holding candidates. The growth forecast embedded in the PAR projection is 10.8% annually.

The complication. Our AI review of Boston Scientific’s last three earnings calls (Q4 2025 through Q2 2026, generated August 11, 2026, so it predates this week’s cyberattack news) flagged a trend it labeled “down” overall. Management cut full-year guidance twice this year, first in Q1 and again in Q2, as its WATCHMAN and electrophysiology franchises, two of its largest growth drivers, decelerated faster than expected. The company responded with a restructuring program aimed at restoring margin expansion by 2028. At the same time, our review noted genuine bright spots: Interventional Cardiology and Neuromodulation both kept growing, and a portion of the business outside WATCHMAN and EP continued performing in line with its historical pattern. Management framed 2028 as the year a wave of new product launches should reaccelerate growth, but acknowledged 2027 will likely remain a difficult bridge year. This week’s cyberattack and guidance warning land on top of that already-bumpy stretch.

Why today, specifically. Boston Scientific’s next earnings report is scheduled for October 28, 2026, where the market will get its first full look at how much the cyberattack actually cost the quarter. For reference, the Wall Street consensus 12-month price target sits at $63.5-66.3 per our data aggregator; that is a different time horizon than our own five-year PAR framework and the two shouldn’t be read as confirming one another.

Put together, this is a case worth studying rather than a straightforward story: exceptional quality and financial strength, a PAR now sitting in the sweet spot largely because of a depressed price, and a near-term earnings picture clouded by both an operational disruption and a franchise-level growth slowdown that predates it. That combination, a high-quality company under real near-term pressure, is exactly the kind of situation where quality metrics and return expectations are worth weighing against each other carefully.

This is educational research, not a recommendation to buy or sell; we’re not taking a position on anyone’s behalf.

Sources

Boston Scientific has also been the In the Sweet Spot pick on: August 11, 2026.

About In the Sweet Spot

Manifest Investing's daily stock pick: one high-quality company whose projected annual return (PAR) sits in the sweet spot above the market median (MIPAR). Each pick pairs Manifest Investing's quality percentile with its projected annual return (PAR); the sweet spot runs from MIPAR + 5 to MIPAR + 10 percentage points. Browse every pick in the archive.

In the Sweet Spot is educational and is not investment advice or a recommendation to buy or sell any security. Figures reflect Manifest Investing's methodology as of the pick date.